established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.
Company profile
Ticker
TARO, TARO
Exchange
Website
CEO
Uday Baldota
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
TARO stock data
Latest filings (excl ownership)
SC 13E3/A
Going private transaction (amended)
15 Apr 24
SC 13E3/A
Going private transaction (amended)
20 Mar 24
SC 13E3/A
Going private transaction (amended)
11 Mar 24
SC 13E3
Going private transaction
15 Feb 24
6-K
Current report (foreign)
26 Jan 24
6-K
Current report (foreign)
17 Jan 24
6-K
Current report (foreign)
4 Jan 24
6-K
Current report (foreign)
11 Dec 23
6-K
Current report (foreign)
17 Nov 23
6-K
Current report (foreign)
27 Oct 23
Transcripts
Latest ownership filings
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
17 Jan 24
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
11 Dec 23
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
26 May 23
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
8 Sep 22
SC 13D/A
Taro Pharmaceutical Industries LTD
27 Nov 13
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
8 Feb 13
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
13 Aug 12
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
18 Oct 11
SC 13D/A
SUN PHARMACEUTICAL INDUSTRIES LTD
19 Jan 11
SC 13D/A
FRANKLIN RESOURCES INC
8 Nov 10
Financial summary
Quarter (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Mar 23 | Mar 22 | Mar 21 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
91.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 70 |
Opened positions | 23 |
Closed positions | 13 |
Increased positions | 22 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 126.14 bn |
Total shares | 34.27 mm |
Total puts | 21.10 k |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
Sun Pharmaceutical Industries | 29.50 mm | $0.00 |
Krensavage Asset Management | 643.08 k | $24.39 mm |
Renaissance Technologies | 594.90 k | $22.57 mm |
BLK Blackrock | 581.84 k | $22.07 bn |
Dimensional Fund Advisors | 552.16 k | $20.94 bn |
Brandes Investment Partners | 472.90 k | $17.94 bn |
Eversept Partners | 250.29 k | $9.49 bn |
Acadian Asset Management | 249.05 k | $9.41 mm |
AMP Ameriprise Financial | 230.26 k | $8.73 bn |
Hotchkis & Wiley Capital Management | 223.54 k | $8.48 bn |
News
Krensavage Asset Management Remains Opposed to Sun Pharma's Predatory Bid for Taro Pharma
30 Jan 24
Taro Pharmaceutical Indus Q3 2024 GAAP EPS $0.54 Beats $0.30 Estimate
25 Jan 24
Taro Pharmaceutical Indus Q3 Sales $157.10M Beat $154.91M Estimate
25 Jan 24
Earnings Scheduled For January 25, 2024
25 Jan 24
Earnings Preview For Taro Pharmaceutical Indus
24 Jan 24
Press releases
Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
15 Apr 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates TAST, TARO, MDC
10 Feb 24
INVESTIGATION ALERT: Halper Sadeh LLC Investigates HARP, TARO, FFNW
6 Feb 24
TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
6 Feb 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates PGTI, TARO, ANSS
30 Jan 24